US7005252B1 - Serum free cultivation of primate embryonic stem cells - Google Patents

Serum free cultivation of primate embryonic stem cells Download PDF

Info

Publication number
US7005252B1
US7005252B1 US09/522,030 US52203000A US7005252B1 US 7005252 B1 US7005252 B1 US 7005252B1 US 52203000 A US52203000 A US 52203000A US 7005252 B1 US7005252 B1 US 7005252B1
Authority
US
United States
Prior art keywords
stem cells
culture
serum
growth factor
embryonic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/522,030
Inventor
James A Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24079156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7005252(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/522,030 priority Critical patent/US7005252B1/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Assigned to WISCONSIN ALUMNI RESEARCH FOUNDATION reassignment WISCONSIN ALUMNI RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THOMSON, JAMES A.
Priority to AU2001241973A priority patent/AU2001241973B2/en
Priority to KR1020027011681A priority patent/KR100795760B1/en
Priority to IL15127001A priority patent/IL151270A0/en
Priority to JP2001565854A priority patent/JP5717311B2/en
Priority to AU4197301A priority patent/AU4197301A/en
Priority to MXPA02008698A priority patent/MXPA02008698A/en
Priority to CA2402299A priority patent/CA2402299C/en
Priority to BR0108507-7A priority patent/BR0108507A/en
Priority to EP01913296.8A priority patent/EP1261691B1/en
Priority to CNB018062350A priority patent/CN100372928C/en
Priority to PCT/US2001/006912 priority patent/WO2001066697A2/en
Priority to NZ520701A priority patent/NZ520701A/en
Priority to IL151270A priority patent/IL151270A/en
Priority to IS6515A priority patent/IS6515A/en
Priority to NO20024200A priority patent/NO335780B1/en
Priority to US10/430,497 priority patent/US7217569B2/en
Priority to HK03106031A priority patent/HK1053616A1/en
Priority to US10/952,096 priority patent/US20050148070A1/en
Priority to US11/078,737 priority patent/US7439064B2/en
Priority to US11/257,704 priority patent/US20060040384A1/en
Publication of US7005252B1 publication Critical patent/US7005252B1/en
Application granted granted Critical
Priority to AU2007200575A priority patent/AU2007200575B2/en
Priority to US12/240,640 priority patent/US20090023208A1/en
Priority to US12/489,978 priority patent/US20100173410A1/en
Priority to JP2011164743A priority patent/JP2011234735A/en
Priority to JP2011164419A priority patent/JP5839666B2/en
Priority to US13/398,933 priority patent/US20120178160A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Definitions

  • the present invention relates to methods for culturing primate embryonic stem cell cultures and culture media useful therewith.
  • mice Although the mouse is the mainstay of experimental mammalian developmental biology, and although many of the fundamental mechanisms that control development are conserved between mice and humans, there are significant differences between early mouse and human development. Primate/human ES cells should therefore provide important new insights into their differentiation and function.
  • ES cell-derived cells Differentiated derivatives of primate ES cells could be used to identify gene targets for new drugs, used to test toxicity or teratogenicy of new compounds, and used for transplantation to replace cell populations in disease.
  • Potential conditions that might be treated by the transplantation of ES cell-derived cells include Parkinson's disease, cardiac infarcts, juvenile-onset diabetes mellitus, and leukemia. See e.g. J. Rossant et al. 17 Nature Biotechnology 23–4 (1999) and J. Gearhart, 282 Science 1061–2 (1998).
  • WO 98/30679 there was a discussion of providing a serum-free supplement in replacement for animal serum to support the growth of certain embryonic stem cells in culture.
  • the serum replacement included albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements. It was noted that this replacement could be further supplemented with leukemia inhibitory factor, steel factor, or ciliary neurotrophic factor. Unfortunately, in the context of primate embryonic stem cell cultures (especially those grown on fibroblast feeder layers), these culture media did not prove satisfactory.
  • nutrient serum culture media e.g. fetal bovine serum
  • WO 99/20741 discusses the benefit of use of various growth factors such as bFGF in culturing primate stem cells.
  • culture media without nutrient serum is not described.
  • the invention provides a method of culturing primate embryonic stem cells.
  • the culture also has a fibroblast feeder layer.
  • Fibroblast growth factors are essential molecules for mammalian development. There are currently nine known fibroblast growth factor ligands and four signaling fibroblast growth factor receptors therefor (and their spliced variants). See generally D. Ornitz et al., 25 J. Biol. Chem. 15292–7 (1996); U.S. Pat. No. 5,453,357. Slight variations in these factors are expected to exist between species, and thus the term fibroblast growth factor is not species limited. However, I prefer to use human fibroblast growth factors, more preferably human basic fibroblast growth factor produced from a recombinant gene. This compound is readily available in quantity from Gibco BRL-Life Technologies and others.
  • the culture may still be essentially free of the specified serum even though a discrete component (e.g. bovine serum albumin) has been isolated from serum and then is exogenously supplied.
  • a discrete component e.g. bovine serum albumin
  • bovine serum albumin e.g. bovine serum albumin
  • the primate embryonic stem cells that are cultured using this method are human embryonic stem cells that are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. They are therefore referred to as being pluripotent.
  • the culturing permits the embryonic stem cells to stably proliferate in culture for over one month (preferably over six months; even more preferably over twelve months) while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
  • the invention provides another method of culturing primate embryonic stem cells.
  • the growth factor is preferably a fibroblast growth factor, it might also be other materials such as certain synthetic small peptides (e.g. produced by recombinant DNA variants or mutants) designed to activate fibroblast growth factor receptors. See generally T. Yamaguchi et al., 152 Dev. Biol. 75–88 (1992)(signaling receptors).
  • the invention provides a culture system for culturing primate embryonic stem cells. It has a fibroblast feeder layer and human basic fibroblast growth factor supplied by other than just the fibroblast feeder layer.
  • the culture system is essentially free of animal serum.
  • Yet another aspect of the invention provides cell lines (preferably cloned cell lines) derived using the above method. “Derived” is used in its broadest sense to cover directly or indirectly derived lines.
  • KnockOutTM SR medium adjuvant a serum-free replacement originally optimized for mouse ES cells (Gibco BRL, Rockville, Md.).
  • the components of KnockOutTM SR medium adjuvant are those described for serum replacements in WO 98/30679.
  • bFGF basic fibroblast growth factor
  • H-9 cultures were dissociated to single cells for 7 minutes with 0.05% trypsin/0.25% EDTA, washed by centrifugation, and plated on mitotically inactivated mouse embryonic fibroblasts (10 5 ES cells per well of a 6-well plate).
  • individual cells were selected by direct observation under a stereomicroscope and transferred by micropipette to individual wells of a 96 well plate containing mouse embryonic fibroblasts feeders with medium containing 20% serum replacer and 4 ng/ml bFGF.
  • H9 cells were expanded by routine passage every 5–7 days with 1 mg/ml collagenase type IV (Gibco BRL, Rockville, Md.).
  • Six months after derivation H9 cells exhibited a normal XX karyotype by standard G-banding techniques (20 chromosomal spreads analyzed).
  • seven months after derivation, in a single karyotype preparation 16/20 chromosomal spreads exhibited a normal XX karyotype, but 4/20 spreads demonstrated random abnormalities, including one with a translocation to chromosome 13 short arm, one with an inverted chromosome 20, one with a translocation to the number 4 short arm, and one with multiple fragmentation.
  • H9 cells exhibited normal karyotypes in all 20 chromosomal spreads examined.
  • exogenous bFGF is very important for continued undifferentiated proliferation of primate embryonic stem cells in the absence of animal serum.
  • serum-free medium lacking exogenous bFGF, human ES cells uniformly differentiated by two weeks of culture. Addition of other factors such as LIF (in the absence of bFGF) did not prevent the differentiation.
  • clones for expansion were selected by placing cells individually into wells of a 96 well plate under direct microscopic observation. Of 192 H-9 cells plated into wells of 96 well plates, two clones were successfully expanded (H-9.1 and H-9.2). Both of these clones were subsequently cultured continuously in media supplemented with serum replacer and bFGF.
  • H9.1 and H9.2 cells both maintained a normal XX karyotype even after more than 8 months of continuous culture after cloning.
  • the H-9.1 and H-9.2 clones maintained the potential to form derivatives of all three embryonic germ layers even after long term culture in serum-free medium. After 6 months of culture, H9.1 and H9.2 clones were confirmed to have normal karyotypes and were then injected into SCID-beige mice.
  • Both H9.1 and H9.2 cells formed teratomas that contained derivatives of all three embryonic germ layers including gut epithelium (endoderm) embryonic kidney, striated muscle, smooth muscle, bone, cartilage (mesoderm), and neural tissue (ectoderm).
  • endoderm gut epithelium
  • striated muscle smooth muscle
  • bone cartilage
  • ectoderm neural tissue
  • the lower cloning efficiency in medium containing serum suggests the presence of compounds in conventionally used serum that are detrimental to stem cell survival, particularly when the cells are dispersed to single cells. Avoiding the use of these compounds is therefore highly desired.
  • the present invention provides methods for culturing primate embryonic stem cells, and culture media for use therewith.

Abstract

Disclosed herein are methods for culturing primate embryonic stem cells. These cells are cultured on a prolonged and stable basis in the presence of exogenously supplied fibroblast growth factor and in the absence of animal serum. Preferably there is also a fibroblast feeder layer. Also disclosed is a culture media containing fibroblast feeder layer and the fibroblast growth factor.

Description

CROSS REFERENCES TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH BACKGROUND OF THE INVENTION
The present invention relates to methods for culturing primate embryonic stem cell cultures and culture media useful therewith.
Primate (e.g. monkey and human) pluripotent embryonic stem cells have been derived from preimplantation embryos. See U.S. Pat. No. 5,843,780 and J. Thomson et al., 282 Science 1145–1147 (1998). The disclosure of these publications and of all other publications referred to herein are incorporated by reference as if fully set forth herein. Notwithstanding prolonged culture, these cells stably maintain a developmental potential to form advanced derivatives of all three embryonic germ layers.
Primate (particularly human) ES cell lines have widespread utility in connection with human developmental biology, drug discovery, drug testing, and transplantation medicine. For example, current knowledge of the post-implantation human embryo is largely based on a limited number of static histological sections. Because of ethical considerations the underlying mechanisms that control the developmental decisions of the early human embryo remain essentially unexplored.
Although the mouse is the mainstay of experimental mammalian developmental biology, and although many of the fundamental mechanisms that control development are conserved between mice and humans, there are significant differences between early mouse and human development. Primate/human ES cells should therefore provide important new insights into their differentiation and function.
Differentiated derivatives of primate ES cells could be used to identify gene targets for new drugs, used to test toxicity or teratogenicy of new compounds, and used for transplantation to replace cell populations in disease. Potential conditions that might be treated by the transplantation of ES cell-derived cells include Parkinson's disease, cardiac infarcts, juvenile-onset diabetes mellitus, and leukemia. See e.g. J. Rossant et al. 17 Nature Biotechnology 23–4 (1999) and J. Gearhart, 282 Science 1061–2 (1998).
Long term proliferative capacity, developmental potential after prolonged culture, and karyotypic stability are key features with respect to the utility of primate embryonic stem cell cultures. Cultures of such cells (especially on fibroblast feeder layers) have typically been supplemented with animal serum (especially fetal bovine serum) to permit the desired proliferation during such culturing.
For example, in U.S. Pat. Nos. 5,453,357, 5,670,372 and 5,690,296 various culture conditions were described, including some using a type of basic fibroblast growth factor together with animal serum. Unfortunately, serum tends to have variable properties from batch to batch, thus affecting culture characteristics.
In WO 98/30679 there was a discussion of providing a serum-free supplement in replacement for animal serum to support the growth of certain embryonic stem cells in culture. The serum replacement included albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements. It was noted that this replacement could be further supplemented with leukemia inhibitory factor, steel factor, or ciliary neurotrophic factor. Unfortunately, in the context of primate embryonic stem cell cultures (especially those grown on fibroblast feeder layers), these culture media did not prove satisfactory.
In the context of nutrient serum culture media (e.g. fetal bovine serum), WO 99/20741 discusses the benefit of use of various growth factors such as bFGF in culturing primate stem cells. However, culture media without nutrient serum is not described.
In U.S. Pat. No. 5,405,772 growth medium for hematopoietic cells and bone marrow stromal cells are described. There is a suggestion to use fibroblast growth factor in a serum-deprived media for this purpose. However, conditions for growth primate of embryonic stem cells are not described.
It can therefore be seen that a need still exists for techniques to stably culture primate embryonic stem cells without the requirement for use of animal serum.
BRIEF SUMMARY OF THE INVENTION
In one aspect the invention provides a method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer. In a preferred form the culture also has a fibroblast feeder layer.
Fibroblast growth factors are essential molecules for mammalian development. There are currently nine known fibroblast growth factor ligands and four signaling fibroblast growth factor receptors therefor (and their spliced variants). See generally D. Ornitz et al., 25 J. Biol. Chem. 15292–7 (1996); U.S. Pat. No. 5,453,357. Slight variations in these factors are expected to exist between species, and thus the term fibroblast growth factor is not species limited. However, I prefer to use human fibroblast growth factors, more preferably human basic fibroblast growth factor produced from a recombinant gene. This compound is readily available in quantity from Gibco BRL-Life Technologies and others.
It should be noted that for purposes of this patent the culture may still be essentially free of the specified serum even though a discrete component (e.g. bovine serum albumin) has been isolated from serum and then is exogenously supplied. The point is that when serum itself is added the variability concerns arise. However, when one or more well defined purified component(s) of such serum is added, they do not.
Preferably the primate embryonic stem cells that are cultured using this method are human embryonic stem cells that are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. They are therefore referred to as being pluripotent.
The culturing permits the embryonic stem cells to stably proliferate in culture for over one month (preferably over six months; even more preferably over twelve months) while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In another aspect the invention provides another method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of a growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is supplied from a source other than just a fibroblast feeder layer. While the growth factor is preferably a fibroblast growth factor, it might also be other materials such as certain synthetic small peptides (e.g. produced by recombinant DNA variants or mutants) designed to activate fibroblast growth factor receptors. See generally T. Yamaguchi et al., 152 Dev. Biol. 75–88 (1992)(signaling receptors).
In yet another aspect the invention provides a culture system for culturing primate embryonic stem cells. It has a fibroblast feeder layer and human basic fibroblast growth factor supplied by other than just the fibroblast feeder layer. The culture system is essentially free of animal serum.
Yet another aspect of the invention provides cell lines (preferably cloned cell lines) derived using the above method. “Derived” is used in its broadest sense to cover directly or indirectly derived lines.
Variability in results due to differences in batches of animal serum is thereby avoided. Further, it has been discovered that avoiding use of animal serum while using fibroblast growth factor can increase the efficiency of cloning.
It is therefore an advantage of the present invention to provide culture conditions for primate embryonic stem cell lines where the conditions are less variable and permit more efficient cloning. Other advantages of the present invention will become apparent after study of the specification and claims.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the following experiments I used the methods and culture systems of the invention to culture human ES cell lines. Two clonally derived human ES cell lines proliferated for over eight months after clonal derivation and maintained the ability to differentiate to advanced derivatives of all three embryonic germ layers.
Techniques for the initial derivation, culture, and characterization of the human ES cell line H9 were described in J. Thomson et al., 282 Science 1145–1147 (1998). In my experiments herein human ES cells were then plated on irradiated (35 gray gamma irradiation) mouse embryonic fibroblast. Culture medium for the present work consisted of 80% “KnockOut”™ Dulbeco's modified Eagle's medium (DMEM) (Gibco BRL, Rockville, Md.), 1 mM L-Glutamine, 0.1 mM-mercaptoethanol, and 1% nonessential amino acids stock (Gibco BRL, Rockville, Md.), supplemented with either 20% fetal bovine serum (HyClone, Logan, Utah) or 20% KnockOut™ SR medium adjuvant, a serum-free replacement originally optimized for mouse ES cells (Gibco BRL, Rockville, Md.). The components of KnockOut™ SR medium adjuvant are those described for serum replacements in WO 98/30679.
In alternative experiments medium was supplemented with either serum or the aforesaid serum replacer KnockOut™ SR medium adjuvant, and either with or without human recombinant basic fibroblast growth factor (bFGF, 4 ng/ml). The preferred concentration range of bFGF in the culture is between 0.1 ng/ml to 500 ng/ml.
To determine cloning efficiency under varying culture conditions, H-9 cultures were dissociated to single cells for 7 minutes with 0.05% trypsin/0.25% EDTA, washed by centrifugation, and plated on mitotically inactivated mouse embryonic fibroblasts (105 ES cells per well of a 6-well plate). To confirm growth from single cells for the derivation of clonal ES cell lines, individual cells were selected by direct observation under a stereomicroscope and transferred by micropipette to individual wells of a 96 well plate containing mouse embryonic fibroblasts feeders with medium containing 20% serum replacer and 4 ng/ml bFGF.
Clones were expanded by routine passage every 5–7 days with 1 mg/ml collagenase type IV (Gibco BRL, Rockville, Md.). Six months after derivation, H9 cells exhibited a normal XX karyotype by standard G-banding techniques (20 chromosomal spreads analyzed). However, seven months after derivation, in a single karyotype preparation, 16/20 chromosomal spreads exhibited a normal XX karyotype, but 4/20 spreads demonstrated random abnormalities, including one with a translocation to chromosome 13 short arm, one with an inverted chromosome 20, one with a translocation to the number 4 short arm, and one with multiple fragmentation. Subsequently, at 8, 10, and 12.75 months after derivation, H9 cells exhibited normal karyotypes in all 20 chromosomal spreads examined.
We observed that the cloning efficiency of human ES cells in previously described culture conditions that included animal serum was poor (regardless of the presence or absence of bFGF). We also observed that in the absence of animal serum the cloning efficiency increased, and increased even more with bFGF.
The data expressed below is the total number of colonies resulting from 105 individualized ES cells plated, +/−standard error of the mean (percent colony cloning efficiency). With 20% fetal serum and no bFGF there was a result of 240+/−28. With 20% serum and bFGF the result was about the same, 260+/−12. In the absence of the serum (presence of 20% serum replacer) the result with no bFGF was 633+/−43 and the result with bFGF was 826+/−61. Thus, serum adversely affected cloning efficiency, and the presence of the bFGF in the absence of serum had an added synergistic benefit insofar as cloning efficiency.
The long term culture of human ES cells in the presence of serum does not require the addition of exogenously supplied bFGF, and (as noted above) the addition of bFGF to serum-containing medium does not significantly increase human ES cell cloning efficiency. However, in serum-free medium, bFGF increased the initial cloning efficiency of human ES cells.
Further, I have discovered that supplying exogenous bFGF is very important for continued undifferentiated proliferation of primate embryonic stem cells in the absence of animal serum. In serum-free medium lacking exogenous bFGF, human ES cells uniformly differentiated by two weeks of culture. Addition of other factors such as LIF (in the absence of bFGF) did not prevent the differentiation.
The results perceived are particularly applicable to clonal lines. In this regard, clones for expansion were selected by placing cells individually into wells of a 96 well plate under direct microscopic observation. Of 192 H-9 cells plated into wells of 96 well plates, two clones were successfully expanded (H-9.1 and H-9.2). Both of these clones were subsequently cultured continuously in media supplemented with serum replacer and bFGF.
H9.1 and H9.2 cells both maintained a normal XX karyotype even after more than 8 months of continuous culture after cloning. The H-9.1 and H-9.2 clones maintained the potential to form derivatives of all three embryonic germ layers even after long term culture in serum-free medium. After 6 months of culture, H9.1 and H9.2 clones were confirmed to have normal karyotypes and were then injected into SCID-beige mice.
Both H9.1 and H9.2 cells formed teratomas that contained derivatives of all three embryonic germ layers including gut epithelium (endoderm) embryonic kidney, striated muscle, smooth muscle, bone, cartilage (mesoderm), and neural tissue (ectoderm). The range of differentiation observed within the teratomas of the high passage H9.1 and H9.2 cells was comparable to that observed in teratomas formed by low passage parental H9 cells.
It should be appreciated from the description above that while animal serum is supportive of growth it is a complex mixture that can contain compounds both beneficial and detrimental to human ES cell culture. Moreover, different serum batches vary widely in their ability to support vigorous undifferentiated proliferation of human ES cells. Replacing serum with a clearly defined component reduces the variability of results associated with this serum batch variation, and should allow more carefully defined differentiation studies.
Further, the lower cloning efficiency in medium containing serum suggests the presence of compounds in conventionally used serum that are detrimental to stem cell survival, particularly when the cells are dispersed to single cells. Avoiding the use of these compounds is therefore highly desired.
The present invention has been described above with respect to its preferred embodiments. Other forms of this concept are also intended to be within the scope of the claims. For example, while recombinantly produced human basic fibroblast growth factor was used in the above experiments, naturally isolated fibroblast growth factor should also be suitable. Further, these techniques should also prove suitable for use on monkey and other primate cell cultures.
Thus, the claims should be looked to in order to judge the full scope of the invention.
INDUSTRIAL APPLICABILITY
The present invention provides methods for culturing primate embryonic stem cells, and culture media for use therewith.

Claims (14)

1. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stern cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied human fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, so that the stern cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
2. The method of claim 1, wherein the culture is essentially free of any animal serum.
3. The method of claim 2, wherein the culture also comprises a fibroblast feeder layer.
4. The method of claim 2, wherein the fibroblast growth factor is basic fibroblast growth factor.
5. The method of claim 4, wherein the fibroblast growth factor is human basic fibroblast growth factor which has been produced from a recombinant gene.
6. The method of claim 5, wherein the human basic fibroblast growth factor is present in the culture in a concentration of at least 0.1 ng/ml for at least a portion of the method.
7. The method of claim 2, wherein the primate embryonic stem cells are human embryonic stem cells.
8. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins minerals, at least one transferrin or transferrin substitute, and at least one in or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied mammalian fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
9. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
10. The method of claim 9, wherein the culture is essentially free of any animal serum.
11. The method of claim 10, wherein the culture also comprises a fibroblast feeder layer.
12. The method of claim 10, wherein the primate embryonic stem cells are human embryonic stem cells.
13. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
14. In a method of culturing primate embryonic stem cells without serum, the improvement comprising:
culturing the primate embryonic stem cells in a culture free of added mammalian fetal serum but including albumin, vitamins, minerals, insulin, and transferrin, and in the presence of fibroblast growth factor that is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
US09/522,030 2000-03-09 2000-03-09 Serum free cultivation of primate embryonic stem cells Expired - Lifetime US7005252B1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
US09/522,030 US7005252B1 (en) 2000-03-09 2000-03-09 Serum free cultivation of primate embryonic stem cells
NZ520701A NZ520701A (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells with fibroblast growth factor supplied seperately from fibroblast feeder layers
AU4197301A AU4197301A (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
KR1020027011681A KR100795760B1 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
IL15127001A IL151270A0 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
JP2001565854A JP5717311B2 (en) 2000-03-09 2001-03-02 Serum-free culture of primate embryonic stem cells
AU2001241973A AU2001241973B2 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
MXPA02008698A MXPA02008698A (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells.
CA2402299A CA2402299C (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
BR0108507-7A BR0108507A (en) 2000-03-09 2001-03-02 Serum-free culture of primate embryonic stem cells
EP01913296.8A EP1261691B1 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
CNB018062350A CN100372928C (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
PCT/US2001/006912 WO2001066697A2 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
IL151270A IL151270A (en) 2000-03-09 2002-08-14 Serum free cultivation of primate embryonic stem cells
IS6515A IS6515A (en) 2000-03-09 2002-08-20 Embryonic cell culture, free of serum
NO20024200A NO335780B1 (en) 2000-03-09 2002-09-03 Culture system to grow primate embryonic stem cells
US10/430,497 US7217569B2 (en) 2000-03-09 2003-05-06 Clonal cultures of primate embryonic stem cells
HK03106031A HK1053616A1 (en) 2000-03-09 2003-08-22 Serum free cultivation of primate embryonic stem cells
US10/952,096 US20050148070A1 (en) 2000-03-09 2004-09-28 Cultivation of primate embryonic stem cells
US11/078,737 US7439064B2 (en) 2000-03-09 2005-03-11 Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US11/257,704 US20060040384A1 (en) 2000-03-09 2005-10-25 Serum free cultivation of primate embryonic stem cells
AU2007200575A AU2007200575B2 (en) 2000-03-09 2007-02-09 Serum free cultivation of primate embryonic stem cells
US12/240,640 US20090023208A1 (en) 2000-03-09 2008-09-29 Cultivation of Primate Embryonic Cells
US12/489,978 US20100173410A1 (en) 2000-03-09 2009-06-23 Cultivation of Primate Embryonic Stem Cells
JP2011164743A JP2011234735A (en) 2000-03-09 2011-07-27 Serum-free cultivation of primate embryonic stem cell
JP2011164419A JP5839666B2 (en) 2000-03-09 2011-07-27 Serum-free culture of primate embryonic stem cells
US13/398,933 US20120178160A1 (en) 2000-03-09 2012-02-17 Cultivation Of Primate Embryonic Stem Cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/522,030 US7005252B1 (en) 2000-03-09 2000-03-09 Serum free cultivation of primate embryonic stem cells

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/430,497 Continuation US7217569B2 (en) 2000-03-09 2003-05-06 Clonal cultures of primate embryonic stem cells
US10/952,096 Continuation-In-Part US20050148070A1 (en) 2000-03-09 2004-09-28 Cultivation of primate embryonic stem cells
US11/257,704 Continuation US20060040384A1 (en) 2000-03-09 2005-10-25 Serum free cultivation of primate embryonic stem cells

Publications (1)

Publication Number Publication Date
US7005252B1 true US7005252B1 (en) 2006-02-28

Family

ID=24079156

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/522,030 Expired - Lifetime US7005252B1 (en) 2000-03-09 2000-03-09 Serum free cultivation of primate embryonic stem cells
US10/430,497 Expired - Lifetime US7217569B2 (en) 2000-03-09 2003-05-06 Clonal cultures of primate embryonic stem cells
US10/952,096 Abandoned US20050148070A1 (en) 2000-03-09 2004-09-28 Cultivation of primate embryonic stem cells
US11/257,704 Abandoned US20060040384A1 (en) 2000-03-09 2005-10-25 Serum free cultivation of primate embryonic stem cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/430,497 Expired - Lifetime US7217569B2 (en) 2000-03-09 2003-05-06 Clonal cultures of primate embryonic stem cells
US10/952,096 Abandoned US20050148070A1 (en) 2000-03-09 2004-09-28 Cultivation of primate embryonic stem cells
US11/257,704 Abandoned US20060040384A1 (en) 2000-03-09 2005-10-25 Serum free cultivation of primate embryonic stem cells

Country Status (15)

Country Link
US (4) US7005252B1 (en)
EP (1) EP1261691B1 (en)
JP (3) JP5717311B2 (en)
KR (1) KR100795760B1 (en)
CN (1) CN100372928C (en)
AU (2) AU4197301A (en)
BR (1) BR0108507A (en)
CA (1) CA2402299C (en)
HK (1) HK1053616A1 (en)
IL (2) IL151270A0 (en)
IS (1) IS6515A (en)
MX (1) MXPA02008698A (en)
NO (1) NO335780B1 (en)
NZ (1) NZ520701A (en)
WO (1) WO2001066697A2 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017589A1 (en) * 2001-01-10 2003-01-23 Ramkumar Mandalam Culture system for rapid expansion of human embryonic stem cells
US20040111285A1 (en) * 2002-04-09 2004-06-10 Mark Germain Method for human pluripotent stem cells
US20050037492A1 (en) * 2000-01-11 2005-02-17 Chunhui Xu Medium for growing human embryonic stem cells
US20050233446A1 (en) * 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
US20060280729A1 (en) * 2005-06-08 2006-12-14 Sanjay Mistry Cellular therapy for ocular degeneration
US20070154957A1 (en) * 2005-10-06 2007-07-05 Doxsey Stephen J Cell division marker
US20070254359A1 (en) * 2006-04-28 2007-11-01 Lifescan, Inc. Differentiation of human embryonic stem cells
US20080171019A1 (en) * 2007-01-17 2008-07-17 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20080219957A1 (en) * 2005-09-02 2008-09-11 Agency Science, Technology And Method of Deriving Mesenchymal Stem Cells
US7439064B2 (en) * 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US20090170198A1 (en) * 2007-11-27 2009-07-02 Alireza Rezania Differentiation of human embryonic stem cells
US20090325294A1 (en) * 2007-07-01 2009-12-31 Shelley Nelson Single pluripotent stem cell culture
US20090325293A1 (en) * 2008-04-24 2009-12-31 Janet Davis Treatment of pluripotent cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US20100112692A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
US20100112693A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
WO2010053472A1 (en) 2008-11-04 2010-05-14 Novocell, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US20100124783A1 (en) * 2008-11-20 2010-05-20 Ya Xiong Chen Methods and Compositions for Cell Attachment and Cultivation on Planar Substrates
US20100129906A1 (en) * 2005-10-07 2010-05-27 Cellartis Ab Method for Obtaining Xeno-Free Hbs Cell line
US20100144033A1 (en) * 2005-06-22 2010-06-10 Ramkumar Mandalam Suspension Culture of Human Embryonic Stem Cells
US20100196910A1 (en) * 2001-07-20 2010-08-05 Technion Research & Development Foundation Ltd. Methods of generating human cardiac cells and tissues and uses thereof
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US20100304481A1 (en) * 2004-09-08 2010-12-02 Thomson James A Medium and culture of embryonic stem cells
WO2011017315A2 (en) 2009-08-03 2011-02-10 Recombinetics, Inc. Methods and compositions for targeted gene modification
US20110076253A1 (en) * 2005-07-29 2011-03-31 Snyder Michael P Defined Culture Conditions of Human Embryonic Stem Cells
US20110091971A1 (en) * 2008-06-30 2011-04-21 Janet Davis Differentiation of Pluripotent Stem Cells
US20110104805A1 (en) * 2009-10-29 2011-05-05 Centocor Ortho Biotech Inc. Pluripotent Stem Cells
US20110136114A1 (en) * 2008-04-30 2011-06-09 Sanbio Inc. Neural regenerating cells with alterations in dna methylation
US20110151560A1 (en) * 2009-12-23 2011-06-23 Jean Xu Differentiation of human embryonic stem cells
US20110151561A1 (en) * 2009-12-23 2011-06-23 Janet Davis Differentiation of human embryonic stem cells
US20110212067A1 (en) * 2010-03-01 2011-09-01 Centocor Ortho Biotech Inc. Methods for Purifying Cells Derived from Pluripotent Stem Cells
US20120156782A1 (en) * 2010-12-17 2012-06-21 Biolamina Ab Cell culture medium
US20120178160A1 (en) * 2000-03-09 2012-07-12 Wicell Research Institute, Inc. Cultivation Of Primate Embryonic Stem Cells
WO2012154344A1 (en) 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
WO2013134378A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US20130273010A1 (en) * 2006-06-20 2013-10-17 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
EP2730649A1 (en) 2012-11-08 2014-05-14 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8778673B2 (en) 2004-12-17 2014-07-15 Lifescan, Inc. Seeding cells on porous supports
US8785185B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8808687B2 (en) 2010-07-12 2014-08-19 Mark Humayun Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
WO2014160413A1 (en) 2013-03-14 2014-10-02 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9181528B2 (en) 2010-08-31 2015-11-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9528090B2 (en) 2010-08-31 2016-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9593305B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10273452B2 (en) 2013-11-21 2019-04-30 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US10280398B2 (en) 2011-11-04 2019-05-07 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US10900022B2 (en) 2013-06-14 2021-01-26 The University Of Queensland Renal progenitor cells
US11268950B2 (en) 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
US11649431B2 (en) 2013-04-26 2023-05-16 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413904B2 (en) * 1998-10-23 2008-08-19 Geron Corporation Human embryonic stem cells having genetic modifications
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
EP1367899A4 (en) 2001-02-14 2004-07-28 Leo T Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7704736B2 (en) * 2001-11-09 2010-04-27 Trustees Of The University Of Pennsylvania Compositions for the derivation of germ cells from stem cells and methods of use thereof
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
EP1539936A2 (en) * 2002-08-22 2005-06-15 Celltran Limited Cell culture surface
CN1717478A (en) * 2002-10-25 2006-01-04 湖南惠霖生命科技有限公司 Be used for the feeder layer of hESC's vitro culture and the method for cultivating embryonic stem cell
GB0304918D0 (en) * 2003-03-05 2003-04-09 Celltran Ltd Cell culture
US7820439B2 (en) 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
JP4676442B2 (en) 2003-12-02 2011-04-27 セラヴィー バイオサイエンシズ エルエルシー Compositions and methods for growing neural progenitor cells
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
DK2722387T3 (en) 2003-12-23 2020-01-20 Viacyte Inc Definitely endoderm
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US20080085554A1 (en) * 2004-02-13 2008-04-10 Norio Nakatsuji Culture Medium for Culturing Feeder Cells for Embryonic Stem Cells Culture and the Prepared Feeder Cells
JP4688793B2 (en) * 2004-03-23 2011-05-25 敏宏 赤池 Proliferation method of pluripotent stem cells
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
KR20070029745A (en) * 2004-05-21 2007-03-14 위셀 리서치 인스티튜트, 인크. Feeder independent extended culture of embryonic stem cells
MX2007000317A (en) 2004-07-09 2007-03-26 Cythera Inc Preprimitive streak and mesendoderm cells.
EP1791952A4 (en) * 2004-08-13 2008-06-11 Univ Georgia Res Found Compositions and methods for self-renewal and differentiation in human embryonic stem cells
ES2800973T3 (en) * 2004-09-28 2021-01-07 Wisconsin Alumni Res Found Primate embryonic stem cell culture
US20060263879A1 (en) * 2004-12-30 2006-11-23 Stemlifeline, Inc. Methods and systems relating to embryonic stem cell lines
US20060275899A1 (en) * 2004-12-30 2006-12-07 Stemlifeline, Inc. Methods and compositions relating to embryonic stem cell lines
CN1298843C (en) * 2005-02-07 2007-02-07 十堰市太和医院 Human embryonic stem cells culture medium without dependent feeding cell
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
KR100670616B1 (en) * 2005-08-25 2007-01-17 주식회사 메디아나전자 Artificial blstocyst for cultivating cells using epithelial cell or fibroblast, cultivating apparatus thereof
WO2007051038A2 (en) 2005-10-27 2007-05-03 Cythera, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
US7413900B2 (en) * 2005-10-31 2008-08-19 President And Fellows Of Harvard College Immortalized fibroblasts
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
WO2007127454A2 (en) 2006-04-28 2007-11-08 Cythera, Inc. Hepatocyte lineage cells
CA2650812C (en) 2006-04-28 2017-12-12 Lifescan, Inc. Differentiation of human embryonic stem cells
CN100465268C (en) * 2006-05-17 2009-03-04 北京大学 Culture method for human embryonic stem cell and special culture medium thereof
US7964402B2 (en) * 2006-05-25 2011-06-21 Sanford-Burnham Medical Research Institute Methods for culture and production of single cell populations of human embryonic stem cells
KR20090085019A (en) * 2006-08-11 2009-08-06 주식회사 엠씨티티 Culture medium for co-culturing of human stem cells and their feeder cells
WO2008048647A1 (en) * 2006-10-17 2008-04-24 Cythera, Inc. Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
CA2670497A1 (en) 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
US10829733B2 (en) * 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
KR20090115142A (en) * 2007-01-30 2009-11-04 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells(mmc)
US7951593B2 (en) * 2007-03-20 2011-05-31 Universite Rene Descartes-Paris V Culture medium for gingival fibroblasts
ES2626656T3 (en) 2007-07-01 2017-07-25 Lifescan, Inc. Single pluripotent stem cell culture
CN101861386A (en) 2007-07-18 2010-10-13 生命扫描有限公司 The differentiation of human embryo stem cell
ES2648128T3 (en) 2007-07-31 2017-12-28 Lifescan, Inc. Differentiation of pluripotent stem cells using human feeder cells
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US20100087002A1 (en) * 2008-02-21 2010-04-08 Benjamin Fryer Methods, Surface Modified Plates and Compositions for Cell Attachment, Cultivation and Detachment
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
DK2283117T3 (en) 2008-04-21 2014-01-20 Viacyte Inc PROCEDURE FOR CLEANING PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
WO2009154606A1 (en) 2008-06-03 2009-12-23 Cythera, Inc. Growth factors for production of definitive endoderm
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
AU2009274517B2 (en) 2008-07-25 2015-03-26 The University Of Georgia Research Foundation, Inc. Compositions for Mesoderm derived ISL1+ Multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
CA3229301A1 (en) 2008-11-14 2010-05-20 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
MX2013001673A (en) 2010-08-12 2013-03-25 Janssen Biotech Inc Treatment of diabetes with pancreatic endocrine precursor cells.
WO2012054896A1 (en) 2010-10-22 2012-04-26 Biotime Inc. Methods of modifying transcriptional regulatory networks in stem cells
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
WO2012170853A1 (en) 2011-06-10 2012-12-13 Wisconsin Alumni Research Foundation ("Warf") Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
JP6301316B2 (en) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Compositions of endoderm cells and liver parenchymal cells and methods of obtaining and using those cells
CN102732477B (en) * 2012-06-15 2013-06-19 江苏瑞思坦生物科技有限公司 Human adipose-derived stem cell serum-free basic medium
EP3483178B1 (en) 2012-07-31 2020-10-28 AgeX Therapeutics, Inc. Methods to produce hla-g-modified cells
US20140178988A1 (en) 2012-10-08 2014-06-26 Biotime, Inc. Differentiated Progeny of Clonal Progenitor Cell Lines
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN104357379B (en) * 2014-09-30 2017-08-08 刘兴宇 Stem cell media
CA3007733A1 (en) 2015-12-07 2017-06-15 Biotime, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
CN109069870B (en) 2016-02-24 2022-04-29 洛克菲勒大学 Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
KR101877793B1 (en) * 2016-07-15 2018-07-13 주식회사 엔바이오텍 Serum-Free Medium Composition for Stem Cell Culture and Methods for Culturing Stem Cells Using the Same
CN106754652B (en) * 2017-03-06 2019-04-02 广州润虹医药科技股份有限公司 IPS cell differentiation at ectoderm progenitor cells serum-free induced medium and abductive approach
CN106754657B (en) * 2017-03-28 2022-07-22 北京赛斯达生物技术有限公司 Serum-free medium for monkey embryonic stem cells
CN114109294A (en) * 2020-08-26 2022-03-01 中石化胜利石油工程有限公司管具技术服务中心 Flashboard dismouting device and control system thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
WO1997047734A1 (en) 1996-06-14 1997-12-18 The Regents Of The University Of California In vitro derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
DE19756864C1 (en) 1997-12-19 1999-04-29 Brüstle Oliver Dr Production of neuronal or glial progenitor cells
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO2000068359A1 (en) 1999-05-07 2000-11-16 University Of Utah Research Foundation Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells
US6245566B1 (en) * 1997-03-31 2001-06-12 The Johns Hopkins University School Of Medicine Human embryonic germ cell line and methods of use
US20020081724A1 (en) 2000-01-11 2002-06-27 Carpenter Melissa K. Techniques for growth and differentiation of human pluripotent stem cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US670372A (en) * 1898-01-13 1901-03-19 William D Carpenter Process of producing casein products.
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5639046A (en) * 1992-07-21 1997-06-17 Fabio Perini S.P.A. Machine and method for the formation of coreless logs of web material
GB9722370D0 (en) * 1997-10-22 1997-12-17 Ici Plc Dye sheet cassette and printing apparatus
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
IL129966A (en) * 1999-05-14 2009-12-24 Technion Res & Dev Foundation ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS
US6750581B2 (en) * 2002-01-24 2004-06-15 Visteon Global Technologies, Inc. Automotive alternator stator assembly with rectangular continuous wire

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5670372A (en) 1992-10-08 1997-09-23 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6200806B1 (en) * 1995-01-20 2001-03-13 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1997047734A1 (en) 1996-06-14 1997-12-18 The Regents Of The University Of California In vitro derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6245566B1 (en) * 1997-03-31 2001-06-12 The Johns Hopkins University School Of Medicine Human embryonic germ cell line and methods of use
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
DE19756864C1 (en) 1997-12-19 1999-04-29 Brüstle Oliver Dr Production of neuronal or glial progenitor cells
WO2000068359A1 (en) 1999-05-07 2000-11-16 University Of Utah Research Foundation Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells
US20020081724A1 (en) 2000-01-11 2002-06-27 Carpenter Melissa K. Techniques for growth and differentiation of human pluripotent stem cells

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AJ Clark et al., Transgenic Animals, "Germ line manipulation: applications in agriculture and biotechnology," Chap. 11, p. 250. *
J Nichols et al., Development,"Establishment of germ-line-competent embryonic stem (ES) cells using differentiation inhibiting activity," 1990, 110, pp. 1341-1348. *
J. Gearhart, New Potential For Human Embryonic Stem Cells, 282 Science 1061-2 (1998).
J. Rossant et al., In Search Of The tabula rasa Of Human Cells, 17 Nature Biotechnology 23-4 (1999).
J. Thomson et al., Embryonic Stem Cell Llnes Drived From Human Blastocysts, 282 Science 1145-1147 (1998).
JA Piedrahita et al., Theriogenology," On the Isolation of Embryonic Stem Cells: Comparative Behavior of Murine, Procine and Ovine Embryos," Nov. 1990, vol. 34, No. 5, pp. 879-901. *
JA Thomson et al., Proc.Natl.Acad.Sci USA, "Isolation of a primate embryonic stem cell line," Aug. 1995, vol. 92, pp. 7844-7848. *
MD Goldsborough et al., Focus, "Serum-Free Culture of Murine Embryonic Stem (ES) Cells,"1998, vol. 20, No. 1,pp. 8-12. *
Mummery et al., "Fibroblast Growth Factor-Mediated Growth Regulation and Receptor Expression in Embryonal Carcinoma and Embryonic Stem Cells and Human Germ Cell Tumours," Biochemical and Biophysical Research Communications 191:188-195 (1993).
Pease et al., "Isolation of Embryonic Stem (ES) Cells in Media Supplemented with Recombinant Leukemia Inhibitory Factor (LIF)," Developmental Biology 141:344-352 (1990).
T. Yamaguchi et al., Expression Of The Fibroblast Growth Factor Receptor FGFR-1/flg During Gastrulation And Segmentation In the Mouse Embryo, 152 Dev. Biol. 75-88 (1992).
YP Cruz et al., Animal Applications of Research in Mammalian Deveolpment,"Origin of Embryonic and Extraembryonic Cell Lineages in Mammalian Embryos," pp. 147-204. *

Cited By (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317101A1 (en) * 1998-10-23 2010-12-16 Geron Corporation Culture System for Rapid Expansion of Human Embryonic Stem Cells
US8951800B2 (en) 1998-10-23 2015-02-10 Asterias Biotherapeutics, Inc. Primate pluripotent stem cell expansion without feeder cells and in the presence of FGF and matrigel or Engelbreth-Holm-Swarm tumor cell preparation
US10059939B2 (en) 1998-10-23 2018-08-28 Asterias Biotherapeutics, Inc. Screening methods for human embryonic stem cells
US20100203633A1 (en) * 1998-10-23 2010-08-12 Ramkumar Mandalam Culture System for Rapid Expansion of Human Embryonic Stem Cells
US8097458B2 (en) 1998-10-23 2012-01-17 Geron Corporation Micro-carrier culture system for rapid expansion of human embryonic stem cells
US20080299582A1 (en) * 1998-10-23 2008-12-04 Geron Corporation Culture System for Rapid Expansion of Human Embryonic Stem Cells
US8637311B2 (en) 1998-10-23 2014-01-28 Asterias Biotherapeutics, Inc. Human embryonic stem cells genetically modified to contain a nucleic acid and cultured with fibroblast growth factor
US20050037492A1 (en) * 2000-01-11 2005-02-17 Chunhui Xu Medium for growing human embryonic stem cells
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7439064B2 (en) * 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US20120178160A1 (en) * 2000-03-09 2012-07-12 Wicell Research Institute, Inc. Cultivation Of Primate Embryonic Stem Cells
US20090023208A1 (en) * 2000-03-09 2009-01-22 Thomson James A Cultivation of Primate Embryonic Cells
US20080020458A9 (en) * 2001-01-10 2008-01-24 Ramkumar Mandalam Culture system for rapid expansion of human embryonic stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20030017589A1 (en) * 2001-01-10 2003-01-23 Ramkumar Mandalam Culture system for rapid expansion of human embryonic stem cells
US20100196910A1 (en) * 2001-07-20 2010-08-05 Technion Research & Development Foundation Ltd. Methods of generating human cardiac cells and tissues and uses thereof
US20040111285A1 (en) * 2002-04-09 2004-06-10 Mark Germain Method for human pluripotent stem cells
US20080241919A1 (en) * 2003-12-31 2008-10-02 The Burnham Institute Of Medical Research Defined media for pluripotent stem cell culture
US20050233446A1 (en) * 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
US8158424B2 (en) 2004-09-08 2012-04-17 Wisconsin Alumni Research Foundation Primate pluripotent stem cells cultured in medium containing gamma-aminobutyric acid, pipecolic acid and lithium
US20100304481A1 (en) * 2004-09-08 2010-12-02 Thomson James A Medium and culture of embryonic stem cells
US8426203B2 (en) 2004-09-08 2013-04-23 Wisconsin Alumni Research Foundation Culture medium containing gamma-aminobutyric acid, pipecolic acid or lithium for the maintenance of stem cells in an undifferentiated state
US8778673B2 (en) 2004-12-17 2014-07-15 Lifescan, Inc. Seeding cells on porous supports
US20060280729A1 (en) * 2005-06-08 2006-12-14 Sanjay Mistry Cellular therapy for ocular degeneration
US9074189B2 (en) 2005-06-08 2015-07-07 Janssen Biotech, Inc. Cellular therapy for ocular degeneration
US10676714B2 (en) 2005-06-22 2020-06-09 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US20100144033A1 (en) * 2005-06-22 2010-06-10 Ramkumar Mandalam Suspension Culture of Human Embryonic Stem Cells
US20110076253A1 (en) * 2005-07-29 2011-03-31 Snyder Michael P Defined Culture Conditions of Human Embryonic Stem Cells
US9101590B2 (en) 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
US20080219957A1 (en) * 2005-09-02 2008-09-11 Agency Science, Technology And Method of Deriving Mesenchymal Stem Cells
US8962318B2 (en) * 2005-09-02 2015-02-24 Agency For Science, Technology And Research Method of deriving mesenchymal stem cells from ES cells using FGF2
US20110117573A1 (en) * 2005-10-06 2011-05-19 University Of Massachusetts Cell division marker
US7682799B2 (en) 2005-10-06 2010-03-23 University Of Massachusetts Cell division marker
US8420306B2 (en) 2005-10-06 2013-04-16 University Of Massachusetts Cell division marker
US9222939B2 (en) 2005-10-06 2015-12-29 University Of Massachusetts Cell division marker
US20070154957A1 (en) * 2005-10-06 2007-07-05 Doxsey Stephen J Cell division marker
US20100129906A1 (en) * 2005-10-07 2010-05-27 Cellartis Ab Method for Obtaining Xeno-Free Hbs Cell line
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US20070254359A1 (en) * 2006-04-28 2007-11-01 Lifescan, Inc. Differentiation of human embryonic stem cells
US9725699B2 (en) 2006-04-28 2017-08-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US20130273010A1 (en) * 2006-06-20 2013-10-17 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
US7883698B2 (en) 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20080171019A1 (en) * 2007-01-17 2008-07-17 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20090325294A1 (en) * 2007-07-01 2009-12-31 Shelley Nelson Single pluripotent stem cell culture
US10316293B2 (en) 2007-07-01 2019-06-11 Janssen Biotech, Inc. Methods for producing single pluripotent stem cells and differentiation thereof
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
US9744195B2 (en) 2007-07-31 2017-08-29 Lifescan, Inc. Differentiation of human embryonic stem cells
US10456424B2 (en) 2007-07-31 2019-10-29 Janssen Biotech, Inc. Pancreatic endocrine cells and methods thereof
US20090170198A1 (en) * 2007-11-27 2009-07-02 Alireza Rezania Differentiation of human embryonic stem cells
US9969982B2 (en) 2007-11-27 2018-05-15 Lifescan, Inc. Differentiation of human embryonic stem cells
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
US11001802B2 (en) 2008-02-21 2021-05-11 Nunc A/S Surface of a vessel with polystyrene, nitrogen, oxygen and a static sessile contact angle for attachment and cultivation of cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US9845460B2 (en) 2008-04-24 2017-12-19 Janssen Biotech, Inc. Treatment of pluripotent cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090325293A1 (en) * 2008-04-24 2009-12-31 Janet Davis Treatment of pluripotent cells
EP3118308A1 (en) 2008-04-30 2017-01-18 SanBio, Inc. Neural regenerating cells with alterations in dna methylation
US20110136114A1 (en) * 2008-04-30 2011-06-09 Sanbio Inc. Neural regenerating cells with alterations in dna methylation
EP3851520A1 (en) 2008-04-30 2021-07-21 SanBio, Inc. Neural regenerating cells with alterations in dna methylation
US10316288B2 (en) 2008-04-30 2019-06-11 Sanbio, Inc. Neural regenerating cells with alterations in DNA methylation
US9593305B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US10351820B2 (en) 2008-06-30 2019-07-16 Janssen Biotech, Inc. Methods for making definitive endoderm using at least GDF-8
US10233421B2 (en) 2008-06-30 2019-03-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US20110091971A1 (en) * 2008-06-30 2011-04-21 Janet Davis Differentiation of Pluripotent Stem Cells
US9593306B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US9388387B2 (en) 2008-10-31 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9752126B2 (en) 2008-10-31 2017-09-05 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US20100112693A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20100112692A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
EP3550012A1 (en) 2008-11-04 2019-10-09 ViaCyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
WO2010053472A1 (en) 2008-11-04 2010-05-14 Novocell, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US20100124783A1 (en) * 2008-11-20 2010-05-20 Ya Xiong Chen Methods and Compositions for Cell Attachment and Cultivation on Planar Substrates
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
US10287546B2 (en) 2009-02-17 2019-05-14 Memorial Sloan Kettering Cancer Center Kits for neural conversion of human embryonic stem cells
US10260041B2 (en) 2009-02-17 2019-04-16 Memorial Sloan Kettering Cancer Center Methods for neural conversion of human embryonic stem cells
US11560546B2 (en) 2009-02-17 2023-01-24 Memorial Sloan Kettering Cancer Center Methods for neural conversion of human embryonic stem cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010124142A2 (en) 2009-04-22 2010-10-28 Cythera, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9988604B2 (en) 2009-04-22 2018-06-05 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9982235B2 (en) 2009-04-22 2018-05-29 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US11905530B2 (en) 2009-04-22 2024-02-20 Viacyte, Inc. Cell encapsulation device comprising a pancreatic progenitor cell population
EP3904505A1 (en) 2009-04-22 2021-11-03 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US10471104B2 (en) 2009-07-20 2019-11-12 Janssen Biotech, Inc. Lowering blood glucose
US8785185B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20110059160A1 (en) * 2009-08-03 2011-03-10 Essner Jeffrey J Methods and compositions for targeted gene modification
WO2011017315A2 (en) 2009-08-03 2011-02-10 Recombinetics, Inc. Methods and compositions for targeted gene modification
US9074224B2 (en) 2009-08-03 2015-07-07 Recombinetics, Inc. Methods and compositions for targeted gene modification
US20110104805A1 (en) * 2009-10-29 2011-05-05 Centocor Ortho Biotech Inc. Pluripotent Stem Cells
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US11850261B2 (en) 2009-11-17 2023-12-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US20110151560A1 (en) * 2009-12-23 2011-06-23 Jean Xu Differentiation of human embryonic stem cells
US9593310B2 (en) 2009-12-23 2017-03-14 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20110151561A1 (en) * 2009-12-23 2011-06-23 Janet Davis Differentiation of human embryonic stem cells
US10704025B2 (en) 2009-12-23 2020-07-07 Janssen Biotech, Inc. Use of noggin, an ALK5 inhibitor and a protein kinase c activator to produce endocrine cells
US9133439B2 (en) 2009-12-23 2015-09-15 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9150833B2 (en) 2009-12-23 2015-10-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10329534B2 (en) 2010-03-01 2019-06-25 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US20110212067A1 (en) * 2010-03-01 2011-09-01 Centocor Ortho Biotech Inc. Methods for Purifying Cells Derived from Pluripotent Stem Cells
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US11154639B2 (en) 2010-07-12 2021-10-26 University Of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
US8808687B2 (en) 2010-07-12 2014-08-19 Mark Humayun Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
US10188769B2 (en) 2010-07-12 2019-01-29 University Of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
US9458430B2 (en) 2010-08-31 2016-10-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9181528B2 (en) 2010-08-31 2015-11-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9528090B2 (en) 2010-08-31 2016-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9951314B2 (en) 2010-08-31 2018-04-24 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10138292B2 (en) * 2010-12-17 2018-11-27 Biolamina Ab Cell culture medium
US20120156782A1 (en) * 2010-12-17 2012-06-21 Biolamina Ab Cell culture medium
US9655927B2 (en) 2011-04-06 2017-05-23 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US11903972B2 (en) 2011-04-06 2024-02-20 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US8785190B2 (en) 2011-04-06 2014-07-22 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US10543234B2 (en) 2011-04-06 2020-01-28 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
USRE46382E1 (en) 2011-04-06 2017-05-02 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
WO2012154344A1 (en) 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US10280398B2 (en) 2011-11-04 2019-05-07 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US10711243B2 (en) 2011-11-04 2020-07-14 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US11318225B2 (en) 2011-12-05 2022-05-03 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US9642940B2 (en) 2011-12-05 2017-05-09 California Institute Of Technology 3-dimensional parylene scaffold cage
US11377640B2 (en) 2011-12-22 2022-07-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
WO2013134378A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US9593307B2 (en) 2012-03-07 2017-03-14 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US10208288B2 (en) 2012-06-08 2019-02-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP4053264A1 (en) 2012-11-08 2022-09-07 ViaCyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
EP2730649A1 (en) 2012-11-08 2014-05-14 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10947511B2 (en) 2012-12-31 2021-03-16 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor
WO2014160413A1 (en) 2013-03-14 2014-10-02 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
US11446335B2 (en) 2013-03-14 2022-09-20 Viacyte, Inc. Cryopreserved endocrine cells that express chromogranin A
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9650610B2 (en) 2013-03-14 2017-05-16 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10376545B2 (en) 2013-03-14 2019-08-13 Viacyte, Inc. Methods for producing hormone secreting cells in a subject
EP3521418A1 (en) 2013-03-14 2019-08-07 ViaCyte, Inc Cell culture
US11649431B2 (en) 2013-04-26 2023-05-16 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
US10900022B2 (en) 2013-06-14 2021-01-26 The University Of Queensland Renal progenitor cells
US11591567B2 (en) 2013-11-21 2023-02-28 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US10273452B2 (en) 2013-11-21 2019-04-30 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10870832B2 (en) 2014-05-16 2020-12-22 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
US11268950B2 (en) 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof

Also Published As

Publication number Publication date
JP5839666B2 (en) 2016-01-06
KR100795760B1 (en) 2008-01-21
CA2402299C (en) 2012-12-18
NO20024200D0 (en) 2002-09-03
US20030190748A1 (en) 2003-10-09
BR0108507A (en) 2002-12-17
EP1261691A2 (en) 2002-12-04
AU2001241973B2 (en) 2006-11-09
US7217569B2 (en) 2007-05-15
MXPA02008698A (en) 2003-04-14
JP5717311B2 (en) 2015-05-13
IL151270A0 (en) 2003-04-10
KR20030032926A (en) 2003-04-26
NO335780B1 (en) 2015-02-16
EP1261691B1 (en) 2013-07-31
JP2012005489A (en) 2012-01-12
JP2003525625A (en) 2003-09-02
AU4197301A (en) 2001-09-17
WO2001066697A2 (en) 2001-09-13
HK1053616A1 (en) 2003-10-31
NZ520701A (en) 2004-03-26
US20050148070A1 (en) 2005-07-07
CA2402299A1 (en) 2001-09-13
IS6515A (en) 2002-08-20
IL151270A (en) 2008-07-08
NO20024200L (en) 2002-09-03
US20060040384A1 (en) 2006-02-23
JP2011234735A (en) 2011-11-24
CN1416345A (en) 2003-05-07
CN100372928C (en) 2008-03-05
WO2001066697A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
US7005252B1 (en) Serum free cultivation of primate embryonic stem cells
AU2001241973A1 (en) Serum free cultivation of primate embryonic stem cells
AU2005289597B2 (en) Cultivation of primate embryonic stem cells
JP5227318B2 (en) Cell growth medium
US20120178160A1 (en) Cultivation Of Primate Embryonic Stem Cells
US7413904B2 (en) Human embryonic stem cells having genetic modifications
AU2007200575B2 (en) Serum free cultivation of primate embryonic stem cells
JP6446496B2 (en) Culture of primate embryonic stem cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THOMSON, JAMES A.;REEL/FRAME:010886/0593

Effective date: 20000307

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12